Application of Natural Products on Angiogenesis-related Diseases

時間地點:02:00 pm, May 18 (Tue), 2021; B1222 Conference Room

研討講者:Shih-Wei Wang Ph. D.

April 27, 2021


Pathological angiogenesis is recognized as a common denominator underlying a variety of deadly and debilitating human diseases, including cancer, age-related macular degeneration (AMD) and various inflammatory diseases. Currently, angiogenesis inhibitors have become attractive strategy for the treatment of cancer and AMD, leading to a breakthrough in pharmacological research. Discovery of bioactive natural products from Chinese herbal medicine, medical plants and marine organisms is the promising strategy for finding new drug candidates. Natural products also have received a considerable attention as shown by the numerous studies published on their broad-spectrum biological activities. However, the anti-angiogenic property of natural products in current scientific literatures has largely remained a mystery. Therefore, we conducted the anti-angiogenesis study in both in vitro and in vivo models for pursuing novel angiogenesis inhibitors from natural products. Several potential candidate inhibitors have been identified in our lab from nature-based resources. The anti-angiogenic effects and mechanisms of these compounds will be discussed in this presentation.


Shih-Wei Wang Ph. D.

Director/Professor of Institute of Biomedical Science,

Mackay Medical College (MMC)

Prof. Shih-Wei Wang

 Dr. Shih-Wei Wang obtained his Ph.D. in pharmacology from National Taiwan University in 2007. He was appointed as an assistant professor in 2009 at the Department of Medicine, Mackay Medical College (MMC), Taiwan. He was promoted to associate professor in 2015, and then promoted to professor in 2019. Since 2021, he was serving as the Director of Institute of Biomedical Sciences in MMC until now. He is also a joint appointment professor in the Department of Medicine in MMC and Graduate Institute of Natural Products in Kaohsiung Medical University. Prof. Wang’s lab is interested in signal transduction and drug discovery in tumor microenvironment. His current research work focuses on the development of novel angiogenesis inhibitors for treatment or prevention of angiogenesis-related diseases. He has published > 110 research papers in SCI journals (H-index: 28), and was awarded 2 US patent and 4 Taiwan patents for the invention of anti-angiogenic strategy.